The Flamma Group has officially opened its current Good Manufacturing Practice (cGMP) plant in Dalian, China, expanding its global pharmaceutical manufacturing footprint. The grand opening ceremony marked the launch of the Flamma Honkai 2 facility, a modern site designed to meet growing demand for high-quality Active Pharmaceutical Ingredients (APIs) and advanced intermediates.
Located in the Songmudao Chemical Park within the Jinpu New District, the new plant features an overall capacity of 200 m³, with 100 m³ dedicated to cGMP production. The facility houses 14 reactor vessels, advanced centrifuges, and multiple dryers, enabling Flamma to offer seamless transitions from early-stage development to clinical and commercial manufacturing. The site is fully integrated with Flamma’s Italian operations, ensuring consistent quality and oversight.
Flamma’s investment in Dalian aligns with its $200 million global expansion strategy, aimed at enhancing supply chain resilience and providing clients with flexible, risk-mitigated manufacturing solutions. The Dalian plant’s strategic location and Italian management oversight offer international clients a secure and efficient partner for pharmaceutical development in China.